Ipsen S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IPSEY | 300558.SZ | 42C.SI | PCRX | 0MTD.IL | IPCALAB.BO | |
|---|---|---|---|---|---|---|
| Market cap | 14.40B | 20.76B | 515.12M | 1.45B | 178.69B | 494.67B |
| P/E (TTM) | 24.3 | 77.9 | — | 104.0 | 50.8 | 37.8 |
| Forward P/E | 3.9 | 29.2 | 247.4 | 10.5 | — | 27.7 |
| Price/book | 2.7 | 3.2 | 33.6 | 2.2 | 5.2 | 6.1 |
| Dividend yield | 1.06% | 0.31% | — | — | — | 0.30% |
| 1-year change | +21.19% | −12.57% | +259.26% | +66.54% | +46.92% | +51.51% |
| Today | −0.12% | +1.62% | −3.09% | +0.03% | +2.36% | −1.18% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All IPSEY news ›Ipsen places €480m bet on Genfit's liver drug elafibranor
Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and now has the help of fellow French pharma group…
Gilead, Ipsen build the case for their PBC drugs at EASL
Gilead Sciences is just a few weeks away from an FDA decision on seladelpar for rare liver disease primary biliary cholangitis (PBC) and will be buoyed by new data pointing to its long-term efficacy and safety. Two-year data from the…
FDA clears Ipsen’s primary biliary cholangitis drug
Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC). Iqirvo (elafibranor) is also the first new therapy…
Mersen S.A. (CBLNY) Q3 2026 Sales/ Trading Statement Call - Slideshow
2026-10-30. The following slide deck was published by Mersen S.A. The following slide deck was published by Mersen S.A. in conjunction with this event.
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight
Oct 02, 2024, 17:31 ET LAS VEGAS, Oct. 2, 2024 /PRNewswire/ -- Primary biliary cholangitis (PBC), previously referred to as primary biliary cirrhosis, is a long-term liver condition characterized by the gradual destruction of the small…
Ipsen: Incorporating solid H1 operational performance + guidance upgrade
Eps change Change in target price € 204 vs 197 +3.25% Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen's near- and mid-term... Ipsen: Incorporating solid H1 operational…
Ipsen Announces Board and Committee Changes
Published on 09/18/2026 at 04:20 am EDT Ipsen announced the co-optation of Mariette Finet as a Director to its Board of Directors, effective September 18, 2026. Mariette Finet succeeded Michèle Ollier, who resigned from her position as…
Ipsen extends its pullback despite AlphaValue
A day after a 1.06% decline, Ipsen's drop is accelerating despite a positive note from AlphaValue. ... The research firm reaffirmed its add recommendation on the pharmaceutical group's stock and slightly raised its price target to â¬204…
Ipsen S.A. (IPSEY) Q2 2026 Sales/Trading Call Transcript
Ipsen S.A. (IPSEY) Q2 2026 Sales/Trading Call October 22, 2026 7:00 AM EDT David Loew - MD, CEO & DirectorAymeric Le Chatelier - Executive VP & CFOChristelle Huguet - Executive VP and Head of R&D Victor Floch - BNP Paribas, Research…
Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance
PARIS, FRANCE, 22 October 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year-to-date and third quarter of 2026. Full-year 2026 guidance Based on the strong…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com5
- marketscreener.com4
- defenseworld.net2
- stocktitan.net2
- pharmaphorum.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.